NeurAxis, Inc. (NRXS)
NYSEAMERICAN: NRXS · Real-Time Price · USD
6.60
-0.53 (-7.43%)
At close: Nov 2, 2026, 4:00 PM EST
6.69
+0.09 (1.36%)
After-hours: Nov 2, 2026, 4:00 PM EST
NeurAxis Revenue
NeurAxis had revenue of $1.93M in the quarter ending June 30, 2026, with 115.72% growth. This brings the company's total for the last twelve months to $5.32M, up 65.22% year-over-year. In the year 2025, NeurAxis had annual revenue of $3.57M with 32.89% growth. That makes NeurAxis the 39,786th largest company in the world by revenue and 5,282nd in the United States.
Revenue (ttm)
$5.32M
Revenue Growth
+65.22%
P/S Ratio
16.84
Revenue / Employee
$221,505
Employees
24
Market Cap
82.88M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.57M | 883.36K | 32.89% |
| Dec 31, 2024 | 2.69M | 225.88K | 9.18% |
| Dec 31, 2023 | 2.46M | -224.69K | -8.37% |
| Dec 31, 2022 | 2.68M | -36.55K | -1.34% |
| Dec 31, 2021 | 2.72M | 791.06K | 40.98% |
| Dec 31, 2020 | 1.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 63.82M |
| Tonix Pharmaceuticals Holding | 29.10M |
| Atara Biotherapeutics | 6.19M |
| Rani Therapeutics Holdings | 4.88M |
| Rallybio | 434.00K |
| Genelux | 8.00K |
NRXS News
- 6 days ago - NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026 - GlobeNewsWire
- 18 days ago - NeurAxis up 7% to $7.01 after announcing new insurer policy coverage - TheFly
- 18 days ago - Aetna deems IB-Stim by NeurAxis medically necessary - TheFly
- 18 days ago - NeurAxis announces medical policy coverage from ‘major’ insurer - TheFly
- 18 days ago - NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives - GlobeNewsWire
- 4 weeks ago - NeurAxis Transcript: Lytham Partners Fall 2026 Investor Conference - Transcripts
- 4 weeks ago - Neuraxis appoints Blanchard as Chief Commercial Officer - TheFly
- 4 weeks ago - NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer - GlobeNewsWire